FORT LAUDERDALE, Fla. — An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation at Retina World Congress.
Ashkan M. Abbey, MD, FASRS, FAAO, told Healio that EYP-1901, also known as Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals), works by inhibiting the intracellular pan-VEGF receptor as well as the PDGF receptor while interacting with the JAK1 receptor. This “multimechanism of action” is designed to treat retinal vascular diseases, he said.
“It uses a bioerodible matrix to consistently elute the drug vorolanib, which is a